Form 4: Turn Therapeutics Executive Acquires Stock Options

Zuraiz Chaudhary, Interim CFO of Turn Therapeutics, acquired 80,000 employee stock options with an exercise price of $3.12.

Summary

• Zuraiz Chaudhary, who holds the titles of Interim Chief Financial Officer, Vice President of Finance, and Chief Accounting Officer at Turn Therapeutics Inc., has acquired 80,000 employee stock options.
• The options have an exercise price of $3.12 per share.
• These options are subject to vesting conditions: 25% vest on the first anniversary of the grant date, and the remaining 75% vest ratably over the subsequent 36 months.
• Vesting is contingent upon continued employment and adherence to the terms of the option award and the Issuer's 2025 Omnibus Incentive Plan.
• The transaction was reported on April 3, 2026, with an earliest transaction date of April 1, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard executive compensation and an alignment of interests, rather than a direct financial performance indicator.

Positives

• The acquisition of stock options by a key executive like the Interim CFO can signal confidence in the company's future prospects.
• The vesting schedule aligns the executive's incentives with long-term company performance and employee retention.

Negatives

• The filing does not contain any negative financial or operational information, as it is a statement of changes in beneficial ownership.

Risks

• The value of the stock options is directly tied to the future performance of Turn Therapeutics' stock price, which is subject to market volatility and company-specific risks.
• Failure to meet continued employment requirements will result in forfeiture of unvested options.

Future Outlook

The vesting schedule of the stock options suggests a forward-looking perspective on the company's growth and the executive's continued involvement over the next four years.

Management Comments

• The filing indicates Zuraiz Chaudhary's roles as Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer.
• The signature indicates the reporting person's acknowledgment and intent to comply with reporting requirements.

Industry Context

StockSavvy.ai notes that the issuance and acquisition of stock options to key executives is a common practice in the biotechnology and pharmaceutical sectors, like Turn Therapeutics, to incentivize performance and align executive interests with shareholder value.

Management Changes

Stakeholder Impact

• Shareholders: The alignment of executive incentives through stock options may positively influence long-term shareholder value if the company performs well.
• Employees: The existence of an incentive plan suggests a broader framework for employee compensation and motivation.
• Management: The filing confirms the roles and compensation structure for key financial leadership.

Next Steps

• The executive will work towards meeting the vesting conditions for the acquired stock options over the next four years.
• The company will continue to operate under its 2025 Omnibus Incentive Plan.

Key Dates

Keywords

Turn Therapeutics, TTRX, Form 4, Stock Options, Beneficial Ownership, Executive Compensation, SEC Filing, Insider Trading, Zuraiz Chaudhary